C-erbB-2 expression is related with pathological progression of gastric cancer: results of a non-radioactive in situ hybridization

被引:1
作者
Wang, Keqiang [1 ]
Liu, Jiangang [2 ]
Duan, Yanchao [3 ]
Wu, Jiafeng [1 ]
Dongye, Shengyi [4 ]
Wang, Yiren [5 ]
Liu, Zhenzhong [2 ]
Han, Guoxin [2 ]
机构
[1] Taishan Med Univ, Affiliated Hosp, Dept Clin Lab, Tai An, Shandong, Peoples R China
[2] Taishan Med Univ, Affiliated Hosp, Dept Gen Surg, Tai An 27100, Shandong, Peoples R China
[3] Taishan Med Univ, Affiliated Hosp, Dept Hematol, Tai An, Shandong, Peoples R China
[4] Taishan Med Univ, Affiliated Hosp, Dept Pathol, Tai An, Shandong, Peoples R China
[5] Qingdao Univ, Med Coll, Med Lab Class, Qingdao, Shandong, Peoples R China
来源
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY | 2017年 / 10卷 / 09期
关键词
Gastric cancer; c-erbB-2; gene; in situ hybridization; HER2;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To study the relationship of c-erbB-2 oncogene expression with major pathological characteristics of gastric cancer (GC) progression. Methods: Eighty-one GC specimens were studied for c-erbB-2 oncogene amplification using non-radioactive in situ hybridization method. The c-erbB-2 overexpression status was correlated with tumor differentiation, tumor invasion and lymph node metastasis. Results: Among the 81 pathology confirmed GC patients, 41 (50.6%) were found to have c-erbB-2 overexpression in cancer tissues. The rate of c-erbB-2 overexpression was significantly higher in those with poor tumor differentiation (63.0%, 29/46) than in those with well differentiated tumor (34.3%, 12/35) (x(2)=6.576, P < 0.001); significantly higher in those that invaded into deep muscle and beyond (55.7%, 39/70) than in those with tumors limited to the superficial muscle (18.2%, 2/11) (x(2)=5.357, P < 0.025); and significantly higher in those with lymph node metastases (59.6%, 34/57) than in those without lymph node involvement (29.2%, 7/24) (x(2)=6.278, P < 0.025). Conclusions: c-erbB-2 oncogene overexpression may indicate a more aggressive biological behavior of the tumor and could be used as a predictive marker for GC pathological progression.
引用
收藏
页码:9649 / 9653
页数:5
相关论文
共 14 条
[1]   Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients [J].
Bhaumik, Sangeet ;
Ahmad, Firoz ;
Das, Bibhu Ranjan .
MEDICAL ONCOLOGY, 2016, 33 (10)
[2]   HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives [J].
Fanotto, Valentina ;
Ongaro, Elena ;
Rihawi, Karim ;
Avallone, Antonio ;
Silvestris, Nicola ;
Fornaro, Lorenzo ;
Vasile, Enrico ;
Antonuzzo, Lorenzo ;
Leone, Francesco ;
Rosati, Gerardo ;
Giuliani, Francesco ;
Bordonaro, Roberto ;
Scartozzi, Mario ;
De Maglio, Giovanna ;
Negri, Francesca V. ;
Fasola, Gianpiero ;
Aprile, Giuseppe .
ONCOTARGET, 2016, 7 (42) :69060-69074
[3]  
Hurvitz Sara A, 2017, Am Soc Clin Oncol Educ Book, V37, P76, DOI 10.14694/EDBK_175630
[4]   Surgical approaches and outcomes in the treatment of gastric cancer [J].
Kim, HJ ;
Karpeh, MS .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (02) :162-169
[5]   HER2 testing in gastric cancer: results of a German expert meeting [J].
Lordick, Florian ;
Al-Batran, Salah-Eddin ;
Dietel, Manfred ;
Gaiser, Timo ;
Hofheinz, Ralf-Dieter ;
Kirchner, Thomas ;
Kreipe, Hans H. ;
Lorenzen, Sylvie ;
Moehler, Markus ;
Quaas, Alexander ;
Roecken, Christoph ;
Rueschoff, Josef ;
Tannapfel, Andrea ;
Thuss-Patience, Peter ;
Baretton, Gustavo .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (05) :835-841
[6]   CHARACTERIZATION OF A GROWTH-FACTOR THAT BINDS EXCLUSIVELY TO THE ERBB-2 RECEPTOR AND INDUCES CELLULAR-RESPONSES [J].
LUPU, R ;
COLOMER, R ;
KANNAN, B ;
LIPPMAN, ME .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (06) :2287-2291
[7]   Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of Syzygium alternifolium through molecular dynamics and pharmacophore-based screening [J].
Muni, Tirumalasetty ;
Babu, Chandra ;
Rammohan, Aluru ;
Baki, Vijaya Bhaskar ;
Devi, Savita ;
Gunasekar, Duvvuru ;
Rajendra, Wudayagiri .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :3611-3632
[8]  
Murray Nigel P, 2015, Asian Pac J Cancer Prev, V16, P6615
[9]   HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research [J].
Pietrantonio, F. ;
Caporale, M. ;
Morano, F. ;
Scartozzi, M. ;
Gloghini, A. ;
De Vita, F. ;
Giommoni, E. ;
Fornaro, L. ;
Aprile, G. ;
Melisi, D. ;
Berenato, R. ;
Mennitto, A. ;
Volpi, C. C. ;
Laterza, M. M. ;
Pusceddu, V. ;
Antonuzzo, L. ;
Vasile, E. ;
Ongaro, E. ;
Simionato, F. ;
de Braud, F. ;
Torri, V. ;
Di Bartolomeo, M. .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (12) :2859-2864
[10]   The HER-2/neu oncogene in tumors of the gastrointestinal tract [J].
Ross, JS ;
McKenna, BJ .
CANCER INVESTIGATION, 2001, 19 (05) :554-568